Get started
Cassava Sciences, Inc.Cassava Sciences, Inc.Cassava Sciences, Inc.

Cassava Sciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SAVA chart


Full chart

Key facts today


Cassava Sciences, Inc. will halt simufilam's development for Alzheimer's by Q2 2025 after Phase 3 REFOCUS-ALZ results showed no significant cognitive improvement over placebo.
Analyze the impactAnalyze the impact

SAVA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪135.26 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.44 USD
Net income (FY)
‪−24.34 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪41.98 M‬
Beta (1Y)
−0.53

Employees


Employees (FY)
30
Change (1Y)
+1 +3.45%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−811.40 K‬ USD

About Cassava Sciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Richard Jon Barry
Website
cassavasciences.com
Headquarters
Austin
Founded
1998
FIGI
BBG000BK9YW3
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SAVA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as SAVA.

Frequently Asked Questions


The current price of SAVA is 1.90 USD — it has decreased by −1.41% in the past 24 hours. Watch Cassava Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cassava Sciences, Inc. stocks are traded under the ticker SAVA.
SAVA stock has risen by 1.45% compared to the previous week, the month change is a 0.72% rise, over the last year Cassava Sciences, Inc. has showed a −90.73% decrease.
We've gathered analysts' opinions on Cassava Sciences, Inc. future price: according to them, SAVA price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Watch SAVA chart and read a more detailed Cassava Sciences, Inc. stock forecast: see what analysts think of Cassava Sciences, Inc. and suggest that you do with its stocks.
SAVA reached its all-time high on Jul 14, 2000 with the price of 184.57 USD, and its all-time low was 0.76 USD and was reached on Dec 24, 2018. View more price dynamics on SAVA chart.
See other stocks reaching their highest and lowest prices.
SAVA stock is 55.54% volatile and has beta coefficient of −0.53. Track Cassava Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cassava Sciences, Inc. there?
Today Cassava Sciences, Inc. has the market capitalization of ‪135.26 M‬, it has increased by 4.21% over the last week.
Yes, you can track Cassava Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Cassava Sciences, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
SAVA net income for the last quarter is ‪−27.60 M‬ USD, while the quarter before that showed ‪−27.94 M‬ USD of net income which accounts for 1.24% change. Track more Cassava Sciences, Inc. financial stats to get the full picture.
No, SAVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 25, 2025, the company has 30.00 employees. See our rating of the largest employees — is Cassava Sciences, Inc. on this list?
Like other stocks, SAVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cassava Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cassava Sciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cassava Sciences, Inc. stock shows the sell signal. See more of Cassava Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.